Sign up Australia
Proactive Investors - Run By Investors For Investors

3D Medical: Mach7 Technologies granted mobile device image capture patent

3D Medical: Mach7 Technologies granted mobile device image capture patent

3D Medical (ASX:3DM) and Mach7 Technologies Pte. Ltd which recently announced an intention to merge have been awarded a U.S. patent for its technology that acquires medical image data from a mobile device and sends that data for patient medical record upload.

The Mach7 technology puts mobile healthcare in the hands of patient-facing clinicians and moves image management closer to the point of care delivery.

This reduces time to diagnose and helps ensure faster care delivery.

Around 60% of medical imaging data is captured outside of digital imaging departments such as radiology and cardiology.

Outside of these two groupings, medical facilities face an uphill battle to optimise workflow to capture medical imaging data digitally and to store and share the data through a patient’s EMR.

Subject to approvals and capital raisings of $10 million, 3D Medical and Mach7 Technologies will change the ASX listed entity name to Mach7 Technologies Limited.

The first $4 million was raised in a placement at $0.075 each while a share purchase plan is also planned.

3D Medical prints 3D models of a patients bones and organs for doctors and surgeons. Mach7 is a United States medical technology business.

3D Medical was the Australian reseller of Mach7's imaging platform.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Register here to be notified of future M7T Company articles
View full M7T profile

Mach7 Technologies Timeline

November 14 2016
November 30 2015

Related Articles

stylised picture with web icons meant to denote a web search
May 11 2016
Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
March 28 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use